医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Global Life Sciences Hiring Index Posts 8% Quarterly Increase Led by Surge in EMEA

2013年04月29日 PM11:40
このエントリーをはてなブックマークに追加


 

WEST ORANGE, N.J.

The first quarter of 2013 showed overall higher levels of demand for Life Sciences talent globally as the ZRG Index edged up to 82.8, an 8% increase over year end levels. New job opportunities increased broadly across Europe and the Americas, while the number of opportunities in the Asia Pacific region fell 23% in the quarter.

What’s Hot?

  • Europe, Middle East and Africa jumped 30% in the quarter.
  • Job opportunities in Regulatory / Quality and Clinical were up substantially with an 80% increase in demand.
  • Medical Device and Diagnostics sectors showed the biggest increase in demand with a 10% rise in opportunity.

What’s Not?

  • The APAC region cooled in Q1 with overall hiring decreasing by 23% in the quarter.
  • Outsourcing and Services sector showed clear pessimism reflected in the level of hiring.
  • Research and Development related jobs dropped across the globe.

Companies have re-engaged efforts in a big way to fill open positions. Commenting on the change of direction, ZRG’s European President and Global Practice Head of Life Sciences Adam El Din related, “Our clients continue to have broad needs that seem to never catch up to the headcount in place. With a competitive market for talent and more demand than supply, the fight for talent continues across all levels with our client organizations.”

About ZRG Partners

ZRG Partners, Inc. is a global authority on talent management issues in the Life Sciences, Pharmaceutical and Medical markets. ZRG provides its clients with specialized global market expertise in executive recruitment, consulting and advisory work with a focus on data and analytics to drive great business decisions.

For a full copy of the report, please go to www.zrgpartners.com

CONTACT

ZRG Partners
Adam
El Din
, +41-22-319-3304
European President and Global Practice
Head of Life Sciences
or
Larry
Hartmann
, +1-201-560-9900 x222
Managing Partner

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表